In today’s recent session, 1.28 million shares of the Adma Biologics Inc (NASDAQ:ADMA) have been traded, and its beta is 0.63. Most recently the company’s share price was $17.79, and it changed around $0.78 or 4.56% from the last close, which brings the market valuation of the company to $4.20B. ADMA at last check was trading at a discount to its 52-week high of $23.64, offering almost -32.88% off that amount. The share price’s 52-week low was $5.68, which indicates that the recent value has risen by an impressive 68.07% since then.
Adma Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ADMA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Adma Biologics Inc is expected to report earnings per share of 0.14 for the current quarter.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Instantly ADMA has been showing a green trend so far today with a performance of 4.56% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 18.25 on recent trading dayincreased the stock’s daily price by 2.52%. The company’s shares are currently up 3.70% year-to-date, but still up 12.71% over the last five days. On the other hand, Adma Biologics Inc (NASDAQ:ADMA) is 7.98% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 1.17% from its current value. Analyst projections state that ADMA is forecast to be at a low of $18 and a high of $18.
Adma Biologics Inc (ADMA) estimates and forecasts
The year-over-year growth rate is expected to be 14.92%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 111.9M in revenue for the current quarter. 1 analysts expect Adma Biologics Inc to make 120.3M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 81.88M and 107.19M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 36.67%. Forecasts for the next quarter put sales growth at 12.23%.
Adma Biologics Inc earnings are expected to increase by 43.56% in 2025, but the outlook is positive 31.08% per year for the next five years.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
VANGUARD GROUP INC, with 6.3426% or 14.52 million shares worth $162.3 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 15.26 shares worth $268.55 million, making up 6.46% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 7.16 shares worth around $125.93 million, which represents about 3.03% of the total shares outstanding.
